CDC Vaccine Committee Charter

What changed in the CDC vaccine committee charter?

The CDC charter dated June 24, 2026, describes ACIP as a federal advisory committee of medical and public health experts that provides recommendations to the CDC Director on vaccines and immunization program strategies. It states that ACIP evaluates evidence on vaccine safety, efficacy, effectiveness and implementation, and that adopted recommendations may become official CDC and HHS guidance.

One closely watched provision says the committee may consider other preventive measures, including non-vaccine interventions, when relevant to assessing appropriate vaccine use. The same section limits that role: ACIP is not being assigned independent authority to issue recommendations for non-vaccine interventions outside its vaccine advisory function.

How could the ACIP charter affect vaccine recommendations?

ACIP recommendations influence routine immunization schedules for children, adolescents and adults in the United States. The charter says the committee should consider disease burden, vaccine safety, effectiveness, changing disease patterns and feasibility of implementation when recommending schedule updates.

The charter also preserves ACIP's role in the Vaccines for Children program, including review of vaccines, dosing schedules and contraindications for eligible children. For clinicians and families, the practical issue is not the charter language alone, but whether future ACIP votes remain transparent, evidence-based and clear enough to support confident vaccination decisions.

Why do evidence review methods matter for vaccine policy?

CDC materials state that ACIP uses the Grading of Recommendations, Assessment, Development and Evaluation approach and Evidence to Recommendations frameworks when developing vaccine guidance. These methods are designed to weigh benefits and harms, evidence certainty, patient values, public health feasibility and economic considerations.

That process is especially important when recommendations affect large populations, such as infants, older adults, pregnant people or people with immune conditions. Transparent evidence tables and public deliberation help clinicians explain why a vaccine is recommended, when it should be delayed, and which groups need individualized medical advice.